PGmax™ - Primary Immunodeficiency and Malignancy Predisposition Panel
Use
This test is for individuals who have relevant clinical features or a suspected diagnosis of primary immunodeficiency or lymphoid malignancy. It is also applicable for those with a family history of such conditions. The panel aims to identify genetic variants associated with primary immunodeficiency disorders and predisposition to lymphoid malignancy, aiding in diagnosis and risk assessment.
Special Instructions
The test includes Exome-Wide CNV Analysis and offers STAT Testing options for expedited results with an additional cost. It is part of the PGmax series developed according to CAP and CLIA regulations but not approved by the FDA.
Limitations
While the test offers comprehensive genetic analysis, it is limited by the detection scope of NGS. Not all genetic variants or CNVs may be covered, especially those outside the panel's specific targets. Rare variants and those of uncertain significance may require additional interpretation.
New York Approved
Methodology
NGS
Biomarkers
Result Turnaround Time
14-28 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided